Platform Success Example II – Insulin Interacting with its Full-Length Receptor
Sanofi wanted to measure the interaction kinetics between insulin and its two binding sites on the full-length insulin receptor, with the ultimate aim to optimize the clinical efficacy of novel insulin analogues.
Biophysical experiments with any full-length transmembrane receptor is a known significant challenge.
Beactica’s team of highly skilled scientists developed an experimental design for SPR biosensor-based studies of the full-length insulin receptor.
The methods developed enable accurate measurements of interaction kinetics between insulin analogues and the two binding sites of full-length insulin receptor isoform A and B.
Results from the collaboration contributed towards the regulatory approval of Insulin lispro Sanofi®, a rapid-acting insulin biosimilar introduced on the market by Sanofi.
Wohlfart P, Gossas T, Lindgren L, Kullman-Magnusson M, and Tennagels N (2017), Poster at International Symposium on Insulin Receptor and Insulin Action IR2017 in Nice, France.